Table S2. Concentrations of serum PON1 and AFP in different groups (sub groups) in both test and validation cohorts.
| Variable | Group | Test | Validation | |||||
|---|---|---|---|---|---|---|---|---|
| No. | Median (IQR) | Mean | No. | Median (IQR) | Mean | |||
| PON1 (ng/mL) | ||||||||
| Total | NVI | 297 | 346.4 (211.0–525.7) | 416.9 | 135 | 505.1 (346.0–614.9) | 660.1 | |
| MVI | 174 | 124.5 (38.4–262.8) | 185.6 | 84 | 160.9 (103.9–188.2) | 178.3 | ||
| GVI | 34 | 46.1 (0.8–160.6) | 98.9 | 30 | 0.0 (0.0–138.7) | 92.3 | ||
| sHCC | NVI | 228 | 338.6 (202.2–521.0) | 414.8 | 103 | 509.9 (365.0–614.2) | 702.8 | |
| MVI | 93 | 129.9 (52.1–233.8) | 182.9 | 47 | 163.4 (102.8–184.7) | 164.7 | ||
| GVI | 10 | 32.3 (9.8–102.9) | 77.0 | 10 | 65.2 (0.0–285.6) | 138.8 | ||
| aHCC | NVI | 69 | 370.2 (235.6–553.4) | 423.8 | 32 | 441.3 (303.7–623.7) | 522.5 | |
| MVI | 81 | 106.4 (19.5–269.2) | 188.7 | 37 | 150.8 (111.0–189.7) | 195.5 | ||
| GVI | 24 | 76.1 (0.0–184.6) | 108.1 | 20 | 0.0 (0.0–115.5) | 69.0 | ||
| AFP (ng/mL) | ||||||||
| Total | NVI | 297 | 10.3 (3.3–113.1) | 578.7 | 135 | 15.3 (4.3–133.7) | 709.6 | |
| MVI | 174 | 41.0 (8.0–1,032.2) | 3,439.5 | 84 | 19.8 (6.1–521.9) | 3,018.9 | ||
| GVI | 34 | 794.8 (164.4–4,368.8) | 9,166.5 | 30 | 40.3 (10.8–4,245.0) | 5,851.1 | ||
| sHCC | NVI | 228 | 9.9 (3.4–104.4) | 209.4 | 103 | 13.6 (3.6–79.0) | 386.3 | |
| MVI | 93 | 16.9 (4.7–172.8) | 401.1 | 47 | 15.3 (6.2–345.6) | 382.9 | ||
| GVI | 10 | 760.4 (441.4–1,087.8) | 726.6 | 10 | 13.4 (9.4–64.6) | 6,500.2 | ||
| aHCC | NVI | 69 | 11.7 (3.3–124.7) | 1,798.9 | 32 | 56.5 (11.0–1,414.2) | 1,750.3 | |
| MVI | 81 | 190.3 (16.1–4517) | 6,928.1 | 37 | 31.3 (6.1–620.0) | 6,367.3 | ||
| GVI | 24 | 794.8 (75.2–10,939.5) | 12,683.1 | 20 | 373.4 (12.6–7,052.0) | 5,526.6 | ||
HCC, hepatocellular carcinoma; NVI, no vascular invasion; MVI, micro-vascular invasion; GVI, gross vascular invasion; AFP, α-fetoprotein; PON1, paraoxonase 1; aHCC, advanced-HCC.